Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hydrogel vehicle Clear all
Not yet recruiting Phase 2 Interventional

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Antimicrobial Activity of IV Clear™ Dressing - Prevention of Antimicrobial Regrowth

NCT01368120
View directory record Official record
Conditions
Skin Flora Infection
Interventions
IV Clear™ Dressing, Tegaderm CHG™, Silicone Vehicle Control Dressing
Device
Lead sponsor
Covalon Technologies Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miamiville, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris

NCT02164084
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 7, 2026, 11:45 PM EDT
Recruiting Phase 3 Interventional

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

NCT04747977
View directory record Official record
Conditions
Dry Eye
Interventions
OTX-DED
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
15
States / cities
Inglewood, California • Mission Hills, California • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10

NCT02322086
View directory record Official record
Conditions
Psoriasis
Interventions
Topical Rose Bengal, 0.005%
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Miami, Florida • Chapel Hill, North Carolina • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 7, 2026, 11:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema

NCT04225611
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Dexamethasone
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Repeat Insult Patch Test of Wound Dressings

NCT01368146
View directory record Official record
Conditions
Skin Sensitization
Interventions
IV Clear™, Tegaderm CHG™, Silicone Vehicle Control Dressing
Device
Lead sponsor
Covalon Technologies Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 7, 2026, 11:45 PM EDT
Not listed Phase 2 Interventional

Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers

NCT04497805
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
ALLO-ASC-SHEET
Biological
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT02034019
View directory record Official record
Conditions
Post Ocular Surgical Inflammation and Pain
Interventions
Dexamethasone, Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 7, 2026, 11:45 PM EDT
Terminated Not applicable Interventional

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

NCT03461354
View directory record Official record
Conditions
Mucositis Oral, Head and Neck Cancer
Interventions
MucoLox, Sodium Bicarbonate
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

NCT03588130
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Carlsbad, California • Fresno, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

Randomized Study of PH-10 for Psoriasis

NCT01247818
View directory record Official record
Conditions
Psoriasis
Interventions
PH-10 (0.002% Rose Bengal), PH-10 (0.005% Rose Bengal), PH-10 (0.01% Rose Bengal), Vehicle
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Oceanside, California • Miami, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Sep 7, 2026, 11:45 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

NCT05157958
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
ALLO-ASC-SHEET, Vehicle Control
Biological · Other
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
4 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

NCT04362670
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OTX-CSI, Placebo Vehicle
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 4 Interventional Results available

A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis

NCT01065714
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Hydrogel vehicle, Eucerin Lotion
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT01666210
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
OTX-DP (Dexamethasone punctum plug), Placebo Vehicle Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 7, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

NCT03754465
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
ALLO-ASC-DFU, Hydrogel SHEET(Vehicle control)
Biological · Procedure
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 7, 2026, 11:45 PM EDT